Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2016 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9JN
Dostinex 0.5 mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablet. Flat, capsule-shaped, 4 × 8 mm, scored, white tablets. |
One Dostinex tablet contains 0.5 mg cabergoline.
Excipients with known effect: Each tablet contains 75.90 mg of lactose.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Cabergoline is a dopaminergic ergoline derivative endowed with a potent and long-lasting PRL-lowering activity. |
| List of Excipients |
|---|
|
Lactose |
Class I amber glass bottles, stoppered with an aluminum tamper-evident screw cap with silica gel insert or high-density polyethylene (HDPE) bottles with child-resistant polypropylene (PP) cap with inner low-density polyethylene (LDPE) desiccant canister containing silica gel.
Each bottle contains 2, 4 or 8 tablets and is enclosed in an outer cardboard carton.
Not all pack sizes may be marketed.
Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9JN
PL 00057/0969
24 June 2002
| Drug | Countries | |
|---|---|---|
| DOSTINEX | Austria, Australia, Brazil, Cyprus, Germany, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Malta, Mexico, Nigeria, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.